{"title":"罗氏：派罗欣造福丙肝患者","authors":["施文"],"dates":[{"year":2001,"month":9,"day":7}],"parts":[{"type":"paragraph","text":"罗氏：派罗欣造福丙肝患者"},{"type":"paragraph","text":"本报讯罗氏公司生产的抗病毒性肝炎特效药派罗欣，日前获得了瑞士国际药品管理署的销售许可，为全球1.7亿丙肝患者带来了福音。丙肝是危及生命的传染性疾病，可导致肝脏炎症、肝硬化甚至肝癌，我国丙肝患者达1300万人。派罗欣消灭肝炎病毒，具有长效、安全、方便等特点。（施文）"}],"comments":[],"comment_pivots":[],"description":"","page_start":10,"page_end":10}